PCSK9 inhibitors patterns of use in France from nationwide repeated cross-sectional and cohort studies. [PDF]
Sci RepSingier A +5 more
europepmc +1 more source
Alirocumab in the Treatment of Hypercholesterolemia
Clinical Medicine Reviews in Therapeutics, 2017 Constantine Kosmas +6 more
openaire +1 more source
A narrative review of PCSK9 inhibitors: from evolocumab to novel discoveries. [PDF]
Front PharmacolLiu HH, Li S, Li JJ.
europepmc +1 more source
When the Target Is Not the Driver: Rethinking LDL in Cardiac Allograft Vasculopathy. [PDF]
CirculationTruby LK, Shapiro MD.
europepmc +1 more source
Proprotein Convertase Subtilisin/Kexin Type 9 and Atherosclerotic Plaque Progression: A Systematic Review and Meta-Analysis of Intravascular Imaging Studies. [PDF]
Rev Cardiovasc MedTheofilis P +8 more
europepmc +1 more source
Efficacy and safety of proprotein convertase subtilisin/kexin type 9 inhibitors for adults with familial hypercholesterolemia: A network meta-analysis. [PDF]
Int J Cardiol Cardiovasc Risk PrevDing W, Sun L, Shi Y, Tian L.
europepmc +1 more source
Which is the optimal choice in lipid-lowering therapy for reducing major cardiovascular events? a network meta-analysis. [PDF]
Front PharmacolNiu Q, Wang Q, Chen F, Li B.
europepmc +1 more source
The effects of cholesterol-lowering drugs on neurocognitive function: systematic review and meta analysis. [PDF]
Front NeurolLi K, Li Y, Jiang X, Zhu Y.
europepmc +1 more source
Cost-utility analysis of PCSK9 inhibitors for hypercholesterolemia: a Chinese healthcare perspective. [PDF]
Front PharmacolHu D +6 more
europepmc +1 more source
Fair pricing, fair access; a systematic review of cost-effectiveness of new hyperlipidemia injectable medication in developing countries. [PDF]
Cost Eff Resour AllocAzari S +8 more
europepmc +1 more source